U.K. Non-Compliant Healthcare Advertising Claims
UK healthcare ads must not make unsubstantiated, guaranteed or fear-based claims and must describe outcomes and practitioners accurately.
UK healthcare ads must not make unsubstantiated, guaranteed or fear-based claims and must describe outcomes and practitioners accurately.
UK law bars advertising prescription-only medicines to the public and requires medicine ads to stay on-licence, with required content for OTC ads.
UK medical device ads must stay within the intended purpose and avoid unsubstantiated, comparative or cure claims.
Italy bans public advertising of prescription medicines and requires consumer ads for non-prescription medicines to carry minimum information, a leaflet invitation and Ministry of Health authorization.
OTC drug marketing to Alaska consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.
OTC drug marketing to Alabama consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.
Alberta regulated health professionals must not advertise falsely or in ways that exploit patient fear or vulnerability.
OTC drug marketing to Arkansas consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.
OTC drug marketing to Arizona consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.
German medical device ads must not mislead about efficacy or certification, promise success, or use misleading testimonials.
California's Sherman Law bars false or misleading drug advertising; OTC drug ads must stay within the product's labeled OTC uses and must not overstate efficacy or regulatory status.
California healing-arts ads must not be false or misleading, create unjustified expectations of results, use altered images, or misstate fees or board certification.
Canadian medical device ads must stay within the licensed indication, not be misleading, and not promote treatment, prevention or cure of Schedule A.1 diseases to the public.
Alabama's medical cannabis program (Alabama Medical Cannabis Commission (AMCC)) bars marketing that appeals to minors, promotes non-medical use or reaches people without a patient registration, or makes cure or safety claims.
Arkansas's medical cannabis program (Arkansas Medical Marijuana Commission) bars marketing that appeals to minors, promotes non-medical use or reaches people without a patient registration, or makes cure or safety claims.
Puerto Rico allows medical cannabis only; marketing should not make cure claims, present cannabis as recreational or card-free, or appeal to minors.
Texas permits only low-THC cannabis for qualifying patients with a registered physician's prescription under TCUP, as expanded by HB 46 (2025); ads must stay within the THC limit, qualifying conditions and patient-only framing.
Wisconsin's Lydia's Law only protects possession of CBD oil with physician certification; hemp CBD may be sold within federal and state hemp THC limits, but ads may not claim state medical authorization or disease benefits.
Hawaii's medical cannabis program (Hawaii Department of Health — Medical Cannabis Registry) bars marketing that appeals to minors, promotes non-medical use or reaches people without a patient registration, or makes cure or safety claims.
Iowa's medical cannabis program (Iowa Department of Health and Human Services (Iowa HHS), Office of Medical Cannabidiol) bars marketing that appeals to minors, promotes non-medical use or reaches people without a patient registration, or makes cure or safety claims.
Kentucky's medical cannabis program (Kentucky Cabinet for Health and Family Services — Office of Medical Cannabis) bars marketing that appeals to minors, promotes non-medical use or reaches people without a patient registration, or makes cure or safety claims.
Louisiana's medical cannabis program (Louisiana Department of Health — Medical Marijuana Program) bars marketing that appeals to minors, promotes non-medical use or reaches people without a patient registration, or makes cure or safety claims.
New Hampshire's medical cannabis program (New Hampshire Department of Health and Human Services — Therapeutic Cannabis Program) bars marketing that appeals to minors, promotes non-medical use or reaches people without a patient registration, or makes cure or safety claims.
North Dakota's medical cannabis program (North Dakota Department of Health and Human Services — Medical Marijuana Division) bars marketing that appeals to minors, promotes non-medical use or reaches people without a patient registration, or makes cure or safety claims.
Oklahoma's medical cannabis program (Oklahoma Medical Marijuana Authority (OMMA)) bars marketing that appeals to minors, promotes non-medical use or reaches people without a patient registration, or makes cure or safety claims.
Pennsylvania's medical cannabis program (Pennsylvania Department of Health — Office of Medical Marijuana) bars marketing that appeals to minors, promotes non-medical use or reaches people without a patient registration, or makes cure or safety claims.
South Dakota's medical cannabis program (South Dakota Department of Health — Medical Cannabis Program) bars marketing that appeals to minors, promotes non-medical use or reaches people without a patient registration, or makes cure or safety claims.
Utah's medical cannabis program (Utah Department of Health and Human Services — Center for Medical Cannabis) bars marketing that appeals to minors, promotes non-medical use or reaches people without a patient registration, or makes cure or safety claims.
Telehealth ads must not overstate what virtual care can do, guarantee prescriptions or outcomes, or imply Medicare or government endorsement.
OTC drug marketing to Colorado consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.
BC physician and clinic ads must not guarantee outcomes, give success rates without a stated basis, or use testimonials as proof of efficacy.
Prohibits false or misleading claims in Canadian healthcare advertising about providers, facilities, services or treatment outcomes.
Connecticut's Food, Drug and Cosmetic Act and CUTPA bar false or misleading OTC drug claims; packaging must carry FDA Drug Facts labeling.
OTC drug marketing to Delaware consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.
Dutch healthcare provider ads must not guarantee outcomes, make unsupported superlative claims, or present individual results or prices misleadingly.
EU health marketing must not falsely claim to cure illness, guarantee outcomes, misuse professional endorsements, or exploit fear or vulnerability.
Advertising prescription-only medicines to the EU general public is prohibited; unbranded disease awareness and materials for health professionals are allowed.
EU food supplement marketing must not make medicinal claims, may use only authorised health claims, and labels and listings must carry the mandatory daily-dose, warning and varied-diet statements.
MDR Art. 7 bars device advertising that misleads about intended purpose, safety or performance, for example by ascribing functions the device lacks or suggesting uses outside its intended purpose.
Public advertising of non-prescription medicines in the EU must identify the ad and the medicine, name it, invite the reader to read the leaflet, and avoid the prohibited claims in Art. 90.
Limits ads for fluoride anticavity products to the monograph's cavity-prevention claim and bars overstated or unsupported drug benefits.
Limits dandruff, seborrheic dermatitis and psoriasis claims to those the OTC monograph permits for the product's active ingredient, and bars cure or permanence claims.
Limits antiperspirant claims to monograph-permitted wetness claims, bars sweat claims for deodorants without an active, and requires the kidney-disease warning on labels.
Cannabis and CBD products that are not FDA-approved drugs may not be marketed with disease, treatment or symptom claims or as FDA approved.
FDA's position is that CBD and THC cannot lawfully be added to foods or beverages or sold as dietary supplements in interstate commerce; hemp seed ingredients are allowed.
Sunscreen, acne and dandruff products must use FDA-permitted claim terms and stay within monograph uses; full Drug Facts statements apply to labels, not to every ad.
Bars cosmetic marketing claims that assert disease treatment or a change in body structure or function, which would make the product an unapproved drug.
Bars supplement disease claims and requires the DSHEA disclaimer with structure/function claims in labeling and a Supplement Facts panel on labels.
Bars supplement marketing that implies a disease effect through product names, images, testimonials, cited publications or disease symptoms.
Bars supplement marketing that positions the product as a substitute for, enhancer of or equivalent to a drug or medical treatment.
Supplements, cosmetics, foods and CBD products become unapproved drugs if their marketing claims to diagnose, treat, cure, mitigate or prevent disease, and cosmetics also may not claim to affect body structure or function.
OTC external drug products covered by 21 CFR 358 (warts, corns and calluses, ingrown toenails, lice, dandruff, seborrheic dermatitis, psoriasis) may only claim the uses and actives in their monograph.
Food and supplement labels may link a substance to reduced disease risk only through FDA-authorized or qualified health claims, in the required form, and only on foods meeting nutrient eligibility; disease treatment claims are not allowed.
Dietary supplement structure/function claims must not be disease claims and must carry FDA's verbatim disclaimer on the label; the manufacturer must notify FDA and hold substantiation.
Homeopathic products are drugs; marketing must not imply FDA approval, must not promote them for serious diseases, and efficacy claims must be scientifically supported or clearly qualified as based only on homeopathic theory.
Infant formula and baby food marketing must not be misleading, including claims of equivalence to breast milk, disease prevention, guaranteed development or absolute contaminant-free status; formulas must meet FDA nutrient and notification requirements.
Device promotion must describe FDA status accurately (cleared, approved or De Novo authorized), must not imply approval from registration, must not promote investigational devices, and restricted-device ads need a brief risk statement.
Cosmetic marketing must stay within cosmetic (appearance) claims, must not imply FDA approval, and cosmetic labels must include MoCRA adverse-event contact information.
Health software marketing must not claim FDA status it lacks, make diagnostic or disease claims for wellness or excluded software, or claim to replace clinicians.
Firm communications sharing scientific information on unapproved uses with HCPs must follow FDA's January 2025 final SIUU guidance: scientifically sound sources, required disclosures, no persuasive elements, and separation from promotion.
GLP-1 ads must not promote diabetes-only brands for weight loss, imply compounded products are FDA-approved or equivalent to brands, guarantee results, or omit risk information for branded drugs.
Prescription drug promotion must stay within the approved indication; information on unapproved uses may be shared only separately from promotion under FDA's safe-harbor guidance or in reply to unsolicited requests.
SaMD marketing must use the correct FDA status term (approved only for PMA devices, cleared for 510(k)), must not imply FDA endorsement or treat registration as approval, and must not claim uses beyond the authorized intended use.
Sexual wellness products that make therapeutic, contraceptive or STI-prevention claims are regulated as medical devices and may make those claims only within an FDA clearance or approval.
Sports supplements may make structure/function claims only with the full FDA disclaimer on labeling and must not make disease or drug-equivalent claims.
Sunscreen marketing must use monograph-consistent claims: no 'sunblock', 'waterproof', 'sweatproof', instant or all-day protection claims, water resistance only as 40 or 80 minutes, and broad-spectrum and skin-cancer claims only for qualifying products.
Telehealth and online pharmacy ads must not claim or imply that compounded drugs are FDA-approved, generic or equivalent to branded drugs, or proven safe and effective, and ads making drug benefit claims must include risk information.
Medical device promotion must stay within the cleared or approved indications; promoting other uses is misbranding, and restricted-device ads need a brief statement of intended uses and risks.
Weight-loss product marketing must avoid unrealistic or drug-equivalent claims and banned ingredients, disclose typical results for testimonials, and carry Supplement Facts and the DSHEA disclaimer on labeling.
Animal drug ads must be truthful and balanced; prescription animal drug ads, including those aimed at owners, must present major risks and must not imply the drug is available without a veterinarian's prescription.
Disease-awareness ads from drug firms may discuss a condition and urge a doctor visit but must not name, cue or point to a specific drug; if they do, they become product ads needing risk information.
Drug firms may not promote prescription drugs for unapproved uses; scientific information on unapproved uses may go to HCPs only if separate from promotion and accompanied by the disclosures in FDA's 2025 guidance.
Prescription drug promotion must not depict or target age groups outside the approved indication and must include labeled age-specific risks when targeting that group.
Reminder ads may name a prescription drug with limited facts but may not state or imply its use or make claims, and are not allowed for drugs with boxed warnings.
Florida's Drug and Cosmetic Act bars false or misleading drug advertising; OTC drug ads must stay within labeled uses and accurately state strength and regulatory status.
Florida physician and practitioner ads must not be false, deceptive or misleading, including unsupported success rates, guarantees and specialty claims.
Sunscreen labels and ads must avoid 'waterproof', 'sweatproof' and 'sunblock', use only 40- or 80-minute water-resistance claims, and limit skin-cancer claims to Broad Spectrum SPF 15+ products.
Alcohol ads may not make health or therapeutic claims and must have substantiation for objective claims such as calories or taste-test wins.
FTC law bars unsubstantiated disease, treatment and drug-replacement claims for CBD and cannabinoid products; a 'not evaluated by FDA' disclaimer does not fix them.
Healthcare service marketing must not make unsupported cure, success-rate, safety or FDA-status claims, and outcome claims need competent and reliable scientific evidence.
Supplement marketing may not make disease or FDA-approval claims, health claims need competent and reliable scientific evidence, and labeling with structure/function claims must carry the FDA disclaimer.
The FTC requires food and beverage health and nutrition advertising claims to be truthful, not misleading and backed by competent and reliable scientific evidence, applying FDA labeling definitions as a benchmark.
Health, safety and efficacy claims for supplements, OTC drugs, health devices and wellness products must be backed by competent and reliable scientific evidence, generally human clinical trials of the product, and non-drug products must not claim to treat or cure disease.
Prohibits false or misleading ads for foods, drugs, devices, cosmetics and supplements, including disease claims, absolute safety claims, misstated FDA status and omitted material risks.
Objective health claims must be backed by competent and reliable scientific evidence, generally well-controlled human clinical trials on the product or an essentially equivalent formulation.
Ads for OTC homeopathic drugs that make efficacy claims must convey that there is no scientific evidence the product works and that the claims rest only on 1700s homeopathic theories most modern experts reject.
Consumer medical device ads must be truthful and substantiated, must state FDA status accurately ('cleared' vs 'approved'; registration is not approval), and must disclose limitations where omission would mislead.
Sexual wellness advertising must be truthful and substantiated: non-drug products may not claim to treat sexual disorders or match prescription drugs, and enlargement, performance and safety claims must not be deceptive.
Sports nutrition ads must not make guaranteed or exaggerated performance or body-composition claims, and testimonials must disclose generally expected results.
Weight-loss ads must not make the FTC Gut Check claims that are almost always false, and testimonials must disclose generally expected results.
OTC drug marketing to Georgia consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.
In Canada, health product ads to the public may not claim to treat or cure Schedule A.1 diseases or exceed authorized claims, and prescription drug ads are limited to name, price and quantity.
Canadian medical device ads must not make treatment or cure claims for Schedule A.1 diseases to the public, misrepresent Health Canada authorization, or make false or misleading claims.
Digital therapeutics and SaMD advertised in Canada may not be promoted to the public as treating, preventing or curing Schedule A.1 diseases, must not be advertised in a false or misleading way, and Class II-IV devices may not be advertised for sale before they are licensed.
OTC drug marketing to Hawaii consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.
OTC drug ads directed to Iowa consumers must not make false or misleading use, efficacy or safety claims or promote uses outside the label; Drug Facts content is checked only on packaging and labels.
OTC drug marketing to Idaho consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.
OTC drug marketing to Illinois consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.
OTC drug marketing to Indiana consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.
OTC drug marketing to Kansas consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.
OTC drug ads directed to Kentucky consumers must not make false or misleading use, efficacy or safety claims or promote uses outside the label; Drug Facts content is checked only on packaging and labels.
OTC drug ads directed to Louisiana consumers must not make false or misleading use, efficacy or safety claims or promote uses outside the label; Drug Facts content is checked only on packaging and labels.
OTC drug ads directed to Massachusetts consumers must not make false or misleading use, efficacy or safety claims or promote uses outside the label; Drug Facts content is checked only on packaging and labels.
Maryland and federal law bar false or misleading OTC drug advertising; ads must not claim cures, FDA approval or prescription strength, or make absolute safety claims beyond the product's labeled uses.
OTC drug ads directed to Maine consumers must not make false or misleading use, efficacy or safety claims or promote uses outside the label; Drug Facts content is checked only on packaging and labels.
Meta CPG and supplement ads must not make disease-treatment, guaranteed-outcome or disease-framed detox or immunity claims; ordinary structure/function claims are allowed.
Meta sports-nutrition ads must avoid steroid-like or guaranteed-results claims, unsafe ingredients, disease claims and creative aimed at minors.
OTC drug ads directed to Minnesota consumers must not make false or misleading use, efficacy or safety claims or promote uses outside the label; Drug Facts content is checked only on packaging and labels.
OTC drug ads directed to Missouri consumers must not make false or misleading use, efficacy or safety claims or promote uses outside the label; Drug Facts content is checked only on packaging and labels.
Mississippi and federal law bar false or misleading OTC drug ads; claims must stay within labeled symptom-relief uses without cure, absolute safety or unsupported superiority claims.
OTC drug ads directed to Montana consumers must not make false or misleading use, efficacy or safety claims or promote uses outside the label; Drug Facts content is checked only on packaging and labels.
Limited-benefit health ads (indemnity, accident-only, specified disease, short-term) must not look like major medical and must make limited benefits clear.
OTC drug ads seen by North Carolina consumers must make only truthful, substantiated claims within labeled OTC indications; Drug Facts, warnings and directions are checked only on packaging and labeling.
North Dakota and federal law bar false or misleading OTC drug ads, including implied prescription strength, cure or guarantee claims and misstated ingredients or uses.
OTC drug advertising to Nebraska consumers must not make deceptive cure, safety, efficacy or FDA-approval claims or promote uses beyond the label.
OTC drug ads seen by New Hampshire consumers must make only truthful, substantiated claims within labeled OTC indications; Drug Facts, warnings and directions are checked only on packaging and labeling.
New Jersey and federal law bar false or misleading OTC drug ads, including cure claims, implied prescription strength, guaranteed or instant relief and misleading endorsements.
OTC drug ads seen by New Mexico consumers must make only truthful, substantiated claims within labeled OTC indications; Drug Facts, warnings and directions are checked only on packaging and labeling.
North Carolina physician ads must not be false, deceptive or unsubstantiated, including guarantees, unsupported success rates and inaccurate board-certification claims.
Nevada and federal law bar false or misleading OTC drug ads; claims must stay within labeled uses without cure, universal-age safety or absolute claims, and packaging must carry Drug Facts.
New York and federal law bar false or misleading OTC drug ads, including cure, prescription-equivalence, unlabeled-use and misleading safety claims.
Ohio and federal law bar false or misleading OTC drug ads, including cure, implied prescription, off-label and guaranteed claims.
Ohio physician ads must not contain false, fraudulent, deceptive or misleading statements, including unjustified expectations of results and unsupported outcome claims.
Oklahoma and federal law bar false or misleading OTC drug ads, including cure, unsourced superiority, off-label and guaranteed claims.
Oregon and federal law bar false or misleading OTC drug ads, including cure claims, unsourced superlatives, unsupported professional endorsements and off-label uses.
Pennsylvania and federal law bar false or misleading OTC drug ads, including cure claims, unsourced pharmacist endorsements, absolute superlatives and off-label uses.
Pennsylvania physician and clinic ads must not make false, deceptive or misleading claims about outcomes, safety, credentials or superiority.
OTC drug ads seen by Rhode Island consumers must make only truthful, substantiated claims within labeled OTC indications; Drug Facts, warnings and directions are checked only on packaging and labeling.
OTC drug ads seen by South Carolina consumers must make only truthful, substantiated claims within labeled OTC indications; Drug Facts, warnings and directions are checked only on packaging and labeling.
South Dakota and federal law bar false or misleading OTC drug ads, including cure or guarantee claims, off-label conditions, downplayed side effects and unsourced clinical claims.
Alaska's pharmacy practice law, enforced by the Alaska Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Alaska pharmacy ads.
Arizona's pharmacy practice law, enforced by the Arizona State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Arizona pharmacy ads.
California's pharmacy practice law, enforced by the California State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in California pharmacy ads.
Colorado's pharmacy practice law, enforced by the Colorado State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Colorado pharmacy ads.
Connecticut pharmacy ads must not misstate drug efficacy or safety, call compounded drugs FDA-approved, make unqualified price claims, offer Rx incentives without federal program exclusions, or offer Rx drugs without a prescription.
District of Columbia pharmacy ads must not misstate drug efficacy or safety, call compounded drugs FDA-approved, make unqualified price claims, offer Rx incentives without federal program exclusions, or offer Rx drugs without a prescription.
Florida's pharmacy practice law, enforced by the Florida Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Florida pharmacy ads.
Georgia's pharmacy practice law, enforced by the Georgia Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Georgia pharmacy ads.
Hawaii's pharmacy practice law, enforced by the Hawaii Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Hawaii pharmacy ads.
Idaho's pharmacy practice law, enforced by the Idaho Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Idaho pharmacy ads.
Illinois pharmacy ads must not misstate drug efficacy or safety, call compounded drugs FDA-approved, make unqualified price claims, offer Rx incentives without federal program exclusions, or offer Rx drugs without a prescription.
Indiana's pharmacy practice law, enforced by the Indiana State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Indiana pharmacy ads.
Iowa's pharmacy practice law, enforced by the Iowa Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Iowa pharmacy ads.
Kansas's pharmacy practice law, enforced by the Kansas State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Kansas pharmacy ads.
Kentucky's pharmacy practice law, enforced by the Kentucky Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Kentucky pharmacy ads.
Louisiana's pharmacy practice law, enforced by the Louisiana Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Louisiana pharmacy ads.
Maine's pharmacy practice law, enforced by the Maine Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Maine pharmacy ads.
Maryland's pharmacy practice law, enforced by the Maryland Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Maryland pharmacy ads.
Massachusetts pharmacy marketing must not misrepresent compounded drugs as FDA-approved, mislead on drug prices or efficacy, or offer copay waivers and coupons to federal health program beneficiaries.
Michigan's pharmacy practice law, enforced by the Michigan Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Michigan pharmacy ads.
Minnesota's pharmacy practice law, enforced by the Minnesota Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Minnesota pharmacy ads.
Mississippi's pharmacy practice law, enforced by the Mississippi Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Mississippi pharmacy ads.
Missouri's pharmacy practice law, enforced by the Missouri State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Missouri pharmacy ads.
Montana's pharmacy practice law, enforced by the Montana Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Montana pharmacy ads.
Nebraska's pharmacy practice law, enforced by the Nebraska Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Nebraska pharmacy ads.
Nevada's pharmacy practice law, enforced by the Nevada State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Nevada pharmacy ads.
New Hampshire's pharmacy practice law, enforced by the New Hampshire Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in New Hampshire pharmacy ads.
New Jersey's pharmacy practice law, enforced by the New Jersey Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in New Jersey pharmacy ads.
New Mexico's pharmacy practice law, enforced by the New Mexico Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in New Mexico pharmacy ads.
New York's pharmacy practice law, enforced by the New York State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in New York pharmacy ads.
North Carolina's pharmacy practice law, enforced by the North Carolina Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in North Carolina pharmacy ads.
North Dakota's pharmacy practice law, enforced by the North Dakota State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in North Dakota pharmacy ads.
Ohio's pharmacy practice law, enforced by the Ohio State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Ohio pharmacy ads.
Oklahoma's pharmacy practice law, enforced by the Oklahoma State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Oklahoma pharmacy ads.
Oregon's pharmacy practice law, enforced by the Oregon State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Oregon pharmacy ads.
Pennsylvania's pharmacy practice law, enforced by the Pennsylvania State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Pennsylvania pharmacy ads.
Rhode Island's pharmacy practice law, enforced by the Rhode Island Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Rhode Island pharmacy ads.
South Carolina's pharmacy practice law, enforced by the South Carolina Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in South Carolina pharmacy ads.
South Dakota's pharmacy practice law, enforced by the South Dakota Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in South Dakota pharmacy ads.
Tennessee's pharmacy practice law, enforced by the Tennessee Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Tennessee pharmacy ads.
Texas's pharmacy practice law, enforced by the Texas State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Texas pharmacy ads.
Utah pharmacy marketing must not misrepresent compounded drugs as FDA-approved, mislead on drug prices or efficacy, or offer copay waivers and coupons to federal health program beneficiaries.
Vermont's pharmacy practice law, enforced by the Vermont Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Vermont pharmacy ads.
Virginia's pharmacy practice law, enforced by the Virginia Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Virginia pharmacy ads.
Washington pharmacy marketing must not misrepresent compounded drugs as FDA-approved, mislead on drug prices or efficacy, or offer copay waivers and coupons to federal health program beneficiaries.
West Virginia's pharmacy practice law, enforced by the West Virginia Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in West Virginia pharmacy ads.
Wisconsin pharmacy marketing must not misrepresent compounded drugs as FDA-approved, mislead on drug prices, efficacy or ownership, or offer copay waivers and coupons to federal health program beneficiaries.
Swiss health insurer ads aimed at the public must not name or promote prescription-only medicines.
Swiss health insurer ads must not promise cures or guaranteed outcomes from covered treatments or overstate what the plan covers.
Texas physician ads must not be false, misleading or deceptive about outcomes, credentials or specialties, and board-certification claims must meet 22 TAC 164.4.
Tennessee and federal law bar false or misleading OTC drug ads, including disease cure claims, risk denial, misleading ingredient comparisons and off-label efficacy claims.
Texas food and beverage marketing must use nutrient content and health claims that meet federal definitions adopted by Texas and must not claim to cure or prevent disease.
Texas and federal law bar false or misleading OTC drug ads, including disease claims, misstated ingredients, prescription-superiority claims and blanket child-safety claims; packaging must carry Drug Facts.
UK doctors must keep information about their services factual and verifiable, avoid guarantees and pressure offers, and give balanced risk information.
UK medical device ads must not misstate the device's regulatory status (for example 'MHRA approved'), promote uses outside its intended purpose, guarantee results or make unsupported efficacy claims.
UK law bans advertising prescription-only medicines to the public and requires all medicine ads to match the product's authorisation, with label-reading invitations on consumer OTC ads.
Unbranded disease-awareness pieces are outside the risk-disclosure rules only while they do not identify or suggest a specific product; brand cues, single-product category claims or a direct bridge to branded content make them promotion.
Prescription drug and biologic promotion may not recommend or suggest any population, dose, regimen, timing or combination that is not in the approved labeling.
UK marketing of software or AI tools with medical-purpose claims must be consistent with their medical-device status, must not claim MHRA approval and must substantiate performance claims.
Utah and federal law bar false or misleading OTC drug ads, including cure claims, misleading safety or dosage statements and unsupported comparisons.
OTC drug advertising and labeling for Virginia consumers must stay within approved labeling and avoid false or unsubstantiated efficacy, safety and comparative claims.
OTC drug advertising to Vermont consumers must stay within approved labeling and avoid false or unsubstantiated efficacy, safety and comparative claims.
Washington and federal law bar false or misleading OTC drug ads, including off-label therapeutic claims, unsourced superlatives, misleading Rx comparisons and blanket safety claims.
West Virginia accident and sickness insurance ads must label limited-benefit products accurately, disclose exclusions and limitations with benefit descriptions and identify the insurer.
OTC drug advertising to Wisconsin consumers must stay within approved labeling and avoid false or unsubstantiated efficacy, safety and comparative claims.
OTC drug advertising to West Virginia consumers must stay within approved labeling and avoid false or unsubstantiated efficacy, safety and comparative claims.
Wyoming and federal law bar false or misleading OTC drug ads, including cure claims, misleading natural or safety claims, implied prescription efficacy and unlimited pediatric claims.
Wyoming cancer and critical illness insurance ads must state that benefits are limited and supplemental, disclose key limitations and avoid exaggerated fear appeals or statistics.